Accessibility Menu
Can-Fite BioPharma logo

Can-Fite BioPharma(NYSEMKT) CANF

Market Cap$6.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-99%
1 Year-75%
1 Month+1%
$3.18
-6.47%
-0.22Today
Can-Fite BioPharma last closing stock price
MetricPriceDate
Last closeUSD 3.182026-08-31
Can-Fite BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.07%USD 3.352026-08-24
1 month+0.95%USD 3.152026-07-31
3 month+2.25%USD 3.112026-06-02
Year to date-20.5%USD 4.002025-12-31
1 year-74.82%USD 12.632025-08-29
3 year-94.46%USD 57.402023-09-01
5 year-99.14%USD 369.002021-09-01
Since inception-99.98%USD 18,000.002012-11-01

Can-Fite BioPharma Financials at a Glance

Market Cap

$6.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$405.00K

Net Income (TTM)

-$9.83M

EPS (TTM)

-$12.45

P/E Ratio

-0.26

Dividend

$0.00

Beta (Volatility)

0.55 (Low)

Price

$3.18

Volume

800

Open

$3.42

Previous Close

$3.18

Daily Range

$3.16 - $3.42

52-Week Range

$2.56 - $13.40

Estimated Earnings Date

Aug 31, 2026

CANF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company focused on developing small molecule therapeutic products. The company targets various medical conditions, including cancers, inflammatory liver disorders, and erectile dysfunction.

Products and Services
  • Primary drug candidate Piclidenoson for psoriasis and COVID-19
  • Namodenoson in Phase III trials for hepatocellular carcinoma
  • CF602 in preclinical development for erectile dysfunction
Growth Outlook
  • Successful Phase III trials for Piclidenoson may lead to market approval
  • Strategic partnerships enhance development and commercialization capabilities
  • Expansion into cannabis-derived formulations for diverse therapeutic applications
Financial Highlights
  • Recent quarterly revenue of $101,500, showing consistent performance
  • Cash and short-term investments total $8.54 million, providing operational stability
  • Current ratio of 3.46 indicates strong liquidity position
Can-Fite BioPharma Ltd. is positioned in the biotechnology sector, focusing on innovative treatments for serious health conditions. The company has made significant strides in clinical trials, particularly with its lead drug candidates, which could potentially address unmet medical needs. The strategic partnerships formed with other pharmaceutical entities further bolster its development and commercialization efforts, enhancing its market presence. Financially, the company has maintained a solid liquidity position, as evidenced by its current ratio, which suggests it can meet short-term obligations effectively. The recent revenue figures indicate a stable operational performance, which is crucial for sustaining ongoing research and development activities. Overall, Can-Fite BioPharma Ltd. presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapeutic solutions.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Motti Farbstein

Website

www.canfite.com

Headquarters

Ramat Gan, 5257346, IL

CANF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-2456.79%

Net Income Margin

-2426.67%

Return on Equity

-201.06%

Return on Capital

-177.10%

Return on Assets

-103.30%

Earnings Yield

-3.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.14M

Volume

800

Avg. Volume

1.39M

Financials (TTM)

Gross Profit

$405.00K

Operating Income

-$9.95M

EBITDA

-$9.93M

Operating Cash Flow

-$8.95M

Capital Expenditure

-$2.00K

Free Cash Flow

-$8.95M

Cash & ST Invst.

$8.54M

Total Debt

$71.00K

Can-Fite BioPharma Performance Analysis

Can-Fite BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 806,831-5.5%
20232023-12-31USD 741,085-8.1%
20242024-12-31USD 677,199-8.6%
20252025-12-31USD 408,213-39.7%
Can-Fite BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-43.6%
Q22025-06-30N/A
Q32025-09-300.5%
Q42025-12-31N/A
Can-Fite BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -74.53-54.8%
20232023-12-31USD -35.73-52.1%
20242024-12-31USD -21.82-38.9%
20252025-12-31USD -12.03-44.9%
Can-Fite BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3112.5%
Q22025-06-30N/A
Q32025-09-30-442.9%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$101.50K

-43.3%

Gross Profit

$101.50K

-43.3%

Gross Margin

100.00%

N/A

Market Cap

$6.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.36M

N/A

Employees

5

N/A

Net Income

-$2.48M

-26.2%

EBITDA

-$2.53M

-25.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$8.54M

+8.3%

Total Debt

$71.00K

-31.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$15.00K

-70.6%

Short Term Debt

$56.00K

+5.7%

Return on Assets

-1.03%

N/A

Return on Invested Capital

-1.47%

N/A

Free Cash Flow

-$2.10M

-16.5%

Operating Cash Flow

-$2.10M

-16.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNGXSoligenix, Inc.
$0.38+0.85%
CNSPCNS Pharmaceuticals, Inc.
$5.98+8.28%
CMNDClearmind Medicine Inc.
$1.94+10.23%
SILOSilo Pharma, Inc.
$2.48-2.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
WETOWetour Robotics
$5.48-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.92+0.00%
IBITiShares Bitcoin Trust
$44.67+0.02%
INTCIntel
$89.51+0.00%

Questions About CANF

What is the current price of Can-Fite BioPharma?

Can-Fite BioPharma is trading at $3.18 per share.

What is the 52-week range for Can-Fite BioPharma?

Over the past 52 weeks, Can-Fite BioPharma has traded between $2.56 and $13.40.

How much debt does Can-Fite BioPharma have?

As of the most recent reporting period, Can-Fite BioPharma reported total debt of $71.00K.

How much cash does Can-Fite BioPharma have on hand?

Can-Fite BioPharma reported $5.53M in cash and cash equivalents in its most recent financial results.

What is Can-Fite BioPharma’s dividend yield?

Can-Fite BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services